Absorption, Distribution, Metabolism, and Excretion of Revefenacin, a Long-Acting Muscarinic Antagonist (LAMA), in Healthy Male Subjects

被引：0
|
作者：
Bourdet, D. [1 ]
Yeola, S. [1 ]
Colson, P. [1 ]
Pendyala, S. [1 ]
Barnes, C. N. [1 ]
Borin, M. [1 ]
机构：
[1] Theravance Biopharma US Inc, San Francisco, CA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3033
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
    James F. Donohue
    Edward Kerwin
    Chris N. Barnes
    Edmund J. Moran
    Brett Haumann
    Glenn D. Crater
    BMC Pulmonary Medicine, 20
  • [32] Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
    Donohue, James F.
    Kerwin, Edward
    Barnes, Chris N.
    Moran, Edmund J.
    Haumann, Brett
    Crater, Glenn D.
    BMC PULMONARY MEDICINE, 2020, 20 (01)
  • [33] Metabolism and Excretion of Asenapine in Healthy Male Subjects
    van de Wetering-Krebbers, S. F. M.
    Jacobs, P. L.
    Kemperman, G. J.
    Spaans, E.
    Peeters, P. A. M.
    Delbressine, L. P. C.
    van Iersel, M. L. P. S.
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (04) : 580 - 590
  • [34] Absorption, distribution, metabolism, and excretion of 14C-Labeled tivantinib (ARQ 197) in healthy male subjects
    Bathala, Mohinder S.
    Nakai, Daisuke
    Murai, Takahiro
    Pickersgill, Fraser
    Zahir, Hamim
    Tokui, Taro
    CANCER RESEARCH, 2012, 72
  • [35] Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
    Fukuda, Nobuhiko
    Horita, Nobuyuki
    Kaneko, Ayami
    Goto, Atsushi
    Kaneko, Takeshi
    Ota, Erika
    Kew, Kayleigh M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (06):
  • [36] Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients
    Decramer, Marc
    Maltais, Francois
    Feldman, Gregory
    Brooks, Jean
    Harris, Stephanie
    Mehta, Rashmi
    Crater, Glenn
    RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY, 2013, 185 (02) : 393 - 399
  • [37] The Effect of Long-acting Muscarinic Antagonist on Airway Inflammation Through Leukotrienes
    Matsuyama, T.
    Machida, K.
    Matsuyama, H.
    Dotake, Y.
    Takagi, K.
    Inoue, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [38] Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium
    Hamelmann, Eckard
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [39] Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease
    Petite, Sarah E.
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (08) : 696 - 705
  • [40] Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators
    Skolnik, Neil S.
    Nguyen, Trang Susan
    Shrestha, Aarisha
    Ray, Riju
    Corbridge, Thomas C.
    Brunton, Stephen A.
    POSTGRADUATE MEDICINE, 2020, 132 (02) : 198 - 205
12345